KEYMED BIO-B (02162.HK) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Dec7

Conuma's Self-Developed New Drug Supicibai Monoclonal Antibody Injection (Kangyueda®) Included in the National Medical Insurance Catalogue

05:00

Dec1

Pacific Securities Gives BUY Rating to CanNova-B

03:20

Nov18

Significant Progress Achieved by Sanofi and Canonic's Dual Antibody Drugs in Respiratory and Autoimmune Diseases

03:21

Nov6

Huatai Securities Maintains Buy Rating on CanNova Biologics Stock

05:11

Nov5

Conuma-B's Self-Developed Drug CM512 I Phase Clinical Trial for Atopic Dermatitis Successful

02:07

Nov3

Goldman Sachs Initiates Coverage of CanNova with Buy Rating

03:47

Schedules & Filings

Schedules

Filings

Aug26

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 272.95 M, Net Income -43.15 M, EPS -0.1641

Mar24

Earning Release(CST)

FY2024 Q4 Earning Release (HKD) Revenue 198.64 M, Net Income -94.95 M, EPS -0.3619

Aug27

Earning Release(CST)

FY2024 Q2 Earning Release (HKD) Revenue 29.38 M, Net Income -180.92 M, EPS -0.693

View More

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change

View More